Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qiagen Sees Brighter Reimbursement Outlook For Companion Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Personalized health care remains an important growth driver for the diagnostics developer, which is juggling some 15 companion diagnostics projects. The reimbursement landscape for FDA-approved tests is improving, Qiagen says.

You may also be interested in...



Diagnostics News: Qiagen Companion Dx; Ortho-Clinical Agreement; BD 510(k)s

Qiagen will co-develop and commercialize a companion diagnostic for AstraZeneca’s Iressa lung-cancer drug under an agreement between the firms. Ortho-Clinical Diagnostics will sell a test system for acute kidney injury. BD nabs 510(k)s for STD assays.

Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence

Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.

Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Topics

Related Companies

UsernamePublicRestriction

Register

MT032633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel